The Foundation for Sarcoidosis Research (FSR) has granted $300,000 in funding to support three scientists embarking on research studies that could lead to advancements in the diagnosis or treatment of sarcoidosis, or in patient care. Each of the three researchers was awarded $100,000 through the FSR’s Pilot…
Cutaneous sarcoidosis patients with lesions on the head and face are significantly more likely to also have cardiac sarcoidosis, which is when the disease reaches the heart, a small study in the U.S. suggests. The findings indicate the distribution of skin lesions is linked to the risk of…
Blood levels of high-sensitivity cardiac troponin T (hs-cTnT), a marker of heart muscle damage, may serve as a prognostic biomarker for adverse events, including death and heart failure, in people with cardiac sarcoidosis, a study in Japan shows. Patients with combined elevated levels of both hs-cTnT and B-type natriuretic…
Black people with sarcoidosis have longer delays in referrals to multidisciplinary care, according to a recent study. Treatment of sarcoidosis changed in 78% of patients after a referral, with no significant differences in race, sex, or ethnicity between those who underwent a change to clinical management and those who…
Cutaneous sarcoidosis, a type of sarcoidosis of the skin, may increase the risk of certain blood cancers, a study suggests. The study, “Hematologic diseases in patients with cutaneous sarcoidosis,” was published as a letter to the editor in The Journal of Dermatology, but the researchers acknowledged…
More than one-third of sarcoidosis patients have abnormalities in the small airways, or bronchioles, according to a study in Italy that looked at small-airway inspection and biopsy using ultrathin tubes. The researchers said this procedure could aid in diagnosing sarcoidosis. Small-airway biopsies yielded high rates of granuloma detection: 65.4%…
A global Phase 3 clinical trial evaluating efzofitimod, Atyr Pharma’s investigational therapy, in people with pulmonary sarcoidosis will continue as planned following a third pre-planned interim safety review. An independent data safety and monitoring board (DSMB) examined available safety and tolerability data from all 268 participants enrolled in…
Kinevant Sciences’ experimental therapy namilumab failed to show a benefit for people with chronic, active pulmonary sarcoidosis in a Phase 2 clinical trial involving more than 100 patients. Based on the negative results of the RESOLVE-Lung study (NCT05314517), the company announced it will be discontinuing further development…
The Foundation for Sarcoidosis Research (FSR) is providing $200,000 in grants to fund research into improving the diagnosis and management of cardiac sarcoidosis. The funding comprises two grants specific to cardiac sarcoidosis, each totaling $100,000. This is double the investment the FSR made last year in…
Elevated blood levels of fatty molecules, or lipids — specifically triglycerides and low-density lipoprotein cholesterol (LDL-c), also known as bad cholesterol — may be linked with an increased risk of developing sarcoidosis, while certain lipid-lowering medications may help reduce the risk. That’s according to a study that looked at…
Get regular updates to your inbox.